valu usd unless otherwis note
organ revenu growth ahead expect
view deliv strong organ revenu growth
top expect ep in-lin us dollar appreci intra-
quarter reduc ep least penni estim revis
ep guidanc would higher fx
light manag commentari fx impact trim
estim reflect view
deliv approxim organ revenu growth
tougher comp ww revenu y/i organ
 organ growth bp
estim achiev better expect result medic
devic diagnost nutrit offset miss establish
pharmaceut non-cor market total compani
organ growth respect
medic devic record highest quarter organ growth sinc
close stj acquisit revenu growth cardiovascular
neuromodul line estim diabet
better ww sale freestyl libr cross
estim electrophysiolog structur heart post
double-digit growth neuromodul sale growth
slow believ may take quarter
invest commerci infrastructur fuel reacceler
growth heart failur sale slump doubl digit growth
recov given immin fda approv destin therapi
organ revenu growth realist start point
set growth driver especi medic devic
diagnost segment underpin faster growth year
action well even though mitraclip may receiv
 regulatori approv secondari mr file
fda come week strength coapt encourag broader
usag especi outsid potenti approv freestyl
libr catalyst anoth year sale
growth diabet diagnost grow
eu penetr alin acceler revenu estim
assum organ growth bp fx headwind
fx bigger factor ep guidanc challeng
noth new multin buyer current level
attribut modest weak share post result
ep guidanc uncertainti around impact currenc
ep guidanc includ fx believ deliv least
ep growth take us trim ep
estim due currenc higher tax rate
await formal guidanc direct exchang rate next
coupl month better assess magnitud fx impact
price prior trade day market close estimate unless otherwis note
cours high-single-digit revenu growth
double-digit ep growth well
product cycl refresh medic devic diagnost
cost synergi stj alr capit deploy
acceler debt repay push abt revenu
ep growth ahead sever med-tech peer
revenu estim impli cc revenu
growth believ upsid
estim ep estim
freestyl libr repres major sourc upsid us
launch strong start growth
continu rapid pace recent eu approv freestyl
libr catalyst approv expect
next year estim ww sale cross
reach close
mitraclip sustain sale growth next
year highli success coapt trial secondari mr
patient open therapi much bigger patient
popul coapt result may also requir chang
on-going trial competitor devic benefit
momentum diagnost continu least
next coupl year alr transact ad
diagnost portfolio receiv fda
approv first two instrument new alin
platform laboratori diagnost other
forthcom alin suit gain good
traction europ five six instrument
commerci avail instrument drive
sustain recoveri pediatr nutrit return
segment mid-single-digit revenu growth
addit establish pharmaceut maintain
cc growth led double-digit growth emerg
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part analysi valu report segment individu
use respect ev/ebitda multipl blend ev/
ebitda multipl ebitda estim
billion yield target key assumpt underli
valuat cc revenu growth cc
growth basi point increas oper
margin year continu debt reduct
 price target impli price-to-earnings multipl
ep estim
arriv upsid scenario ev/ebitda multipl
ebitda estim billion key
differ base-cas assumpt cc
revenu growth basi point ebit
margin expans year due higher revenu growth
faster realiz cost synergi integr
stj alr capit deploy share repurchas
downsid scenario ebitda
billion key differ base-cas assumpt
mid-single-digit cc organ revenu growth
basi point ebit margin expans
year due slower revenu growth slower
realiz cost synergi
exhibit estim vs report result
exhibit contribut variou segment revenu growth geographi
exhibit revenu growth exclud fx variou busi unit compris medic devic segment
geographi worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl growth excl exhibit revenu growth exclud fx variou busi unit compris diagnost segment
exhibit revenu growth exclud fx variou busi unit compris nutrit segment
exhibit revenu growth exclud fx establish pharmaceut
revenu growth excl laboratori laboratori excl rapid growth excl growth excl emerg pharmaceut medic suppli devic
exhibit revenu model
geographi worldwiderevenu revenu growth growth revenu growth growth revenu growth revenu excl medic suppli devic
sum-of-the-part valuat abt five major busi base ebitda estim
yield price target individu ev/ebitda multipl use valuat
establish pharmaceut multipl along ebitda
estim busi give blend ev/ebitda estim consolid ebitda
billion target impli multipl ep estim
share current trade around ep estim price target
basi outperform rate
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
